NASDAQ:MRUS - Merus Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$18.00 +0.09 (+0.50 %)
(As of 05/21/2018 03:07 PM ET)
Previous Close$17.91
Today's Range$17.86 - $18.13
52-Week Range$13.23 - $22.00
Volume1,884 shs
Average Volume35,648 shs
Market Capitalization$405.21 million
P/E Ratio-4.22
Dividend YieldN/A
Beta0.15

About Merus (NASDAQ:MRUS)

Merus logoMerus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer. Its pre-clinical bispecific antibody candidates include MCLA-134 and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Incyte and ONO Pharmaceutical Co., Ltd. to develop bispecific antibody candidates based on Biclonics technology platform; collaboration agreement with Ono Pharmaceutical Co., Ltd. for the development of human bispecific antibodies; and strategic research collaboration agreement with the Vall d'Hebron Institute of Oncology to develop novel agents for therapeutic applications. Merus N.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.

Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-30-253-8800

Debt

Debt-to-Equity RatioN/A
Current Ratio10.05
Quick Ratio10.05

Price-To-Earnings

Trailing P/E Ratio-4.22
Forward P/E Ratio-4.90
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.36 million
Price / Sales26.52
Cash FlowN/A
Price / CashN/A
Book Value$2.79 per share
Price / Book6.45

Profitability

EPS (Most Recent Fiscal Year)($4.29)
Net Income$-82,610,000.00
Net Margins-530.70%
Return on Equity-91.14%
Return on Assets-28.35%

Miscellaneous

Employees51
Outstanding Shares22,630,000

Merus (NASDAQ:MRUS) Frequently Asked Questions

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) released its earnings results on Thursday, April, 26th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter. The biotechnology company earned $4.49 million during the quarter. Merus had a negative net margin of 530.70% and a negative return on equity of 91.14%. View Merus' Earnings History.

When is Merus' next earnings date?

Merus is scheduled to release their next quarterly earnings announcement on Tuesday, July, 10th 2018. View Earnings Estimates for Merus.

What price target have analysts set for MRUS?

3 equities research analysts have issued 12-month price objectives for Merus' stock. Their predictions range from $28.00 to $32.00. On average, they anticipate Merus' share price to reach $30.00 in the next year. View Analyst Ratings for Merus.

Who are some of Merus' key competitors?

Who are Merus' key executives?

Merus' management team includes the folowing people:
  • Dr. Ton Logtenberg Ph.D., Co-Founder, CEO & Exec. Director (Age 60)
  • Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
  • Mr. John J. Crowley, CFO & Exec. VP (Age 44)
  • Mr. John de Kruif Ph.D., CTO & Sr. VP
  • Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 51)

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Has Merus been receiving favorable news coverage?

Media coverage about MRUS stock has trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Merus earned a news impact score of 0.09 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 44.58 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Merus' major shareholders?

Merus' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (10.80%), BVF Inc. IL (10.69%), Sofinnova Ventures Inc (8.67%), Rock Springs Capital Management LP (0.77%), Iguana Healthcare Management LLC (0.33%) and Stanley Laman Group Ltd. (0.24%). View Institutional Ownership Trends for Merus.

Which institutional investors are selling Merus stock?

MRUS stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP and Iguana Healthcare Management LLC. View Insider Buying and Selling for Merus.

Which institutional investors are buying Merus stock?

MRUS stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Sofinnova Ventures Inc, Stanley Laman Group Ltd. and Millennium Management LLC. View Insider Buying and Selling for Merus.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $18.00.

How big of a company is Merus?

Merus has a market capitalization of $405.21 million and generates $15.36 million in revenue each year. The biotechnology company earns $-82,610,000.00 in net income (profit) each year or ($4.29) on an earnings per share basis. Merus employs 51 workers across the globe.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-30-253-8800 or via email at [email protected]


MarketBeat Community Rating for Merus (MRUS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Merus (NASDAQ:MRUS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Merus in the last 12 months. Their average twelve-month price target is $30.00, suggesting that the stock has a possible upside of 66.67%. The high price target for MRUS is $32.00 and the low price target for MRUS is $28.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.502.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.00$30.00$30.25$30.25
Price Target Upside: 66.67% upside57.15% upside58.46% upside85.81% upside

Merus (NASDAQ:MRUS) Consensus Price Target History

Price Target History for Merus (NASDAQ:MRUS)

Merus (NASDAQ:MRUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/30/2018WedbushReiterated RatingOutperform$26.00 ➝ $32.00LowView Rating Details
1/2/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$28.00HighView Rating Details
10/26/2017Jefferies GroupReiterated RatingBuy$30.00N/AView Rating Details
3/21/2017CitigroupDowngradeBuy ➝ Neutral$31.00HighView Rating Details
6/13/2016GuggenheimInitiated CoverageBuy$18.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Merus (NASDAQ:MRUS) Earnings History and Estimates Chart

Earnings by Quarter for Merus (NASDAQ:MRUS)

Merus (NASDAQ:MRUS) Earnings Estimates

2018 EPS Consensus Estimate: ($3.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.81)($0.81)($0.81)
Q2 20181($0.90)($0.90)($0.90)
Q3 20181($0.98)($0.98)($0.98)
Q4 20181($1.08)($1.08)($1.08)

Merus (NASDAQ MRUS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/10/2018        
4/26/2018Q4 2017($0.86)$4.49 millionViewN/AView Earnings Details
11/30/2017Q3 2017($0.69)($0.95)$2.54 million$4.08 millionViewN/AView Earnings Details
9/19/2017Q2 2017($0.67)($0.56)$2.59 million$4.43 millionViewN/AView Earnings Details
7/11/2017Q1 2017($1.23)$13.12 million$2.44 millionViewN/AView Earnings Details
4/28/2017Q4 2016($2.06)$1.04 million$1.20 millionViewN/AView Earnings Details
11/7/2016Q3($0.51)($0.31)$1.32 millionViewN/AView Earnings Details
8/8/2016Q2 2016($0.52)($0.45)$0.52 million$1.24 millionViewN/AView Earnings Details
7/12/2016Q1 2016($0.69)$0.55 million$0.93 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Merus (NASDAQ:MRUS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Merus (NASDAQ MRUS) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 43.74%
Insider Trading History for Merus (NASDAQ:MRUS)
Institutional Ownership by Quarter for Merus (NASDAQ:MRUS)

Merus (NASDAQ MRUS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Merus (NASDAQ MRUS) News Headlines

Source:
DateHeadline
Merus N.V. (MRUS) Says Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer CellMerus N.V. (MRUS) Says Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell
www.streetinsider.com - May 15 at 10:02 AM
Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer CellMerus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell
finance.yahoo.com - May 15 at 10:02 AM
Merus (MRUS) Cut to Sell at BidaskClubMerus (MRUS) Cut to Sell at BidaskClub
www.americanbankingnews.com - May 15 at 12:36 AM
Head-To-Head Analysis: Merus (MRUS) and Tocagen (TOCA)Head-To-Head Analysis: Merus (MRUS) and Tocagen (TOCA)
www.americanbankingnews.com - May 13 at 1:23 AM
Zacks Investment Research Downgrades Merus (MRUS) to HoldZacks Investment Research Downgrades Merus (MRUS) to Hold
www.americanbankingnews.com - May 9 at 8:52 AM
Merus (MRUS) Raised to Buy at Zacks Investment ResearchMerus (MRUS) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 4 at 10:07 AM
Blog Exposure - VIVUS to Acquire Janssen Pharma’s PANCREAZE(R) Capsules in the United States and CanadaBlog Exposure - VIVUS to Acquire Janssen Pharma’s PANCREAZE(R) Capsules in the United States and Canada
finance.yahoo.com - May 3 at 9:23 AM
Analysts Offer Predictions for Merus Q1 2018 Earnings (MRUS)Analysts Offer Predictions for Merus' Q1 2018 Earnings (MRUS)
www.americanbankingnews.com - May 3 at 6:57 AM
Merus (MRUS) Expected to Earn FY2022 Earnings of ($2.46) Per ShareMerus (MRUS) Expected to Earn FY2022 Earnings of ($2.46) Per Share
www.americanbankingnews.com - May 2 at 10:22 AM
Merus (MRUS) Receives "Outperform" Rating from WedbushMerus (MRUS) Receives "Outperform" Rating from Wedbush
www.americanbankingnews.com - April 30 at 8:57 AM
Merus (MRUS) Lifted to "Hold" at BidaskClubMerus (MRUS) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - April 27 at 9:55 AM
Merus (MRUS) Receives Consensus Rating of "Hold" from AnalystsMerus (MRUS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 27 at 1:28 AM
Merus N.V. to Host Earnings CallMerus N.V. to Host Earnings Call
finance.yahoo.com - April 26 at 9:19 AM
Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017
finance.yahoo.com - April 26 at 9:19 AM
Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018
feeds.benzinga.com - April 19 at 7:34 AM
Merus (MRUS) Scheduled to Post Earnings on ThursdayMerus (MRUS) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - April 19 at 1:02 AM
ValuEngine Lowers Merus (MRUS) to SellValuEngine Lowers Merus (MRUS) to Sell
www.americanbankingnews.com - April 8 at 11:48 AM
Merus (MRUS) Downgraded by BidaskClub to SellMerus (MRUS) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - April 7 at 9:29 AM
Merus (MRUS) Raised to Sell at ValuEngineMerus (MRUS) Raised to Sell at ValuEngine
www.americanbankingnews.com - April 3 at 11:38 AM
Merus NV (MRUS) Receives Average Rating of "Hold" from AnalystsMerus NV (MRUS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 2 at 1:30 AM
Merus (MRUS) Cut to Sector Perform at Royal Bank of CanadaMerus (MRUS) Cut to Sector Perform at Royal Bank of Canada
www.americanbankingnews.com - March 31 at 12:49 PM
Merus (MRUS) Rating Increased to Hold at BidaskClubMerus (MRUS) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 24 at 6:14 PM
$2.72 Million in Sales Expected for Merus NV (MRUS) This Quarter$2.72 Million in Sales Expected for Merus NV (MRUS) This Quarter
www.americanbankingnews.com - March 22 at 1:52 AM
Merus and the Vall dHebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of CancerMerus and the Vall d'Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer
finance.yahoo.com - March 20 at 9:45 AM
Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune DiseasesMerus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases
finance.yahoo.com - March 14 at 10:34 AM
Merus Intellectual Property Portfolio Expands with Two New PatentsMerus' Intellectual Property Portfolio Expands with Two New Patents
finance.yahoo.com - March 13 at 9:50 AM
Merus NV (MRUS) Receives Average Recommendation of "Hold" from BrokeragesMerus NV (MRUS) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 8 at 1:27 AM
Zacks: Analysts Expect Merus NV (MRUS) Will Post Quarterly Sales of $2.72 MillionZacks: Analysts Expect Merus NV (MRUS) Will Post Quarterly Sales of $2.72 Million
www.americanbankingnews.com - March 5 at 2:30 AM
-$0.71 Earnings Per Share Expected for Merus NV (MRUS) This Quarter-$0.71 Earnings Per Share Expected for Merus NV (MRUS) This Quarter
www.americanbankingnews.com - March 3 at 7:20 PM
Merus (MRUS) Stock Rating Upgraded by BidaskClubMerus (MRUS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 24 at 10:54 PM
Merus Announces $55.8 Million Private Placement Offering of Common StockMerus Announces $55.8 Million Private Placement Offering of Common Stock
finance.yahoo.com - February 22 at 9:20 AM
Merus (MRUS) Lowered to Strong Sell at BidaskClubMerus (MRUS) Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - February 18 at 2:18 PM
 Analysts Anticipate Merus NV (MRUS) Will Announce Quarterly Sales of $2.72 Million Analysts Anticipate Merus NV (MRUS) Will Announce Quarterly Sales of $2.72 Million
www.americanbankingnews.com - February 17 at 10:26 AM
Merus NV (MRUS) Expected to Announce Earnings of -$0.71 Per ShareMerus NV (MRUS) Expected to Announce Earnings of -$0.71 Per Share
www.americanbankingnews.com - February 15 at 3:18 AM
Merus Announces Participation in Four Investor Conferences in February 2018Merus Announces Participation in Four Investor Conferences in February 2018
finance.yahoo.com - February 13 at 9:05 AM
Merus NV (MRUS) Given Consensus Recommendation of "Hold" by AnalystsMerus NV (MRUS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 11 at 1:28 AM
Merus NV (MRUS) Expected to Post Quarterly Sales of $2.72 MillionMerus NV (MRUS) Expected to Post Quarterly Sales of $2.72 Million
www.americanbankingnews.com - January 31 at 6:24 AM
Blog Exposure - Merus Reports First Patient Dosed In Phase-2 Clinical Trial of MCLA-128 In Two MBC Patient PopulationsBlog Exposure - Merus Reports First Patient Dosed In Phase-2 Clinical Trial of MCLA-128 In Two MBC Patient Populations
finance.yahoo.com - January 29 at 9:13 AM
Zacks: Analysts Anticipate Merus NV (MRUS) to Announce -$0.71 Earnings Per ShareZacks: Analysts Anticipate Merus NV (MRUS) to Announce -$0.71 Earnings Per Share
www.americanbankingnews.com - January 29 at 3:14 AM
Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient PopulationsMerus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
finance.yahoo.com - January 26 at 9:13 AM
Merus NV (MRUS) Given Average Rating of "Hold" by BrokeragesMerus NV (MRUS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 17 at 2:12 AM
Wedbush Reaffirms "Outperform" Rating for Merus (MRUS)Wedbush Reaffirms "Outperform" Rating for Merus (MRUS)
www.americanbankingnews.com - January 12 at 9:38 AM
Zacks: Brokerages Anticipate Merus NV (MRUS) Will Post Earnings of -$0.71 Per ShareZacks: Brokerages Anticipate Merus NV (MRUS) Will Post Earnings of -$0.71 Per Share
www.americanbankingnews.com - January 12 at 5:14 AM
BRIEF-Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific AntibodiesBRIEF-Merus And Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies
finance.yahoo.com - January 8 at 10:08 AM
Merus and Simcere Announce Strategic Collaboration on Multiple Bispecific AntibodiesMerus and Simcere Announce Strategic Collaboration on Multiple Bispecific Antibodies
finance.yahoo.com - January 8 at 10:08 AM
Merus Provides Clinical Updates for MCLA-117 and MCLA-158 ProgramsMerus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs
finance.yahoo.com - January 4 at 9:50 AM
Merus to Present at the 36th Annual J.P. Morgan Healthcare ConferenceMerus to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 9:48 AM
Merus (MRUS) Upgraded by BidaskClub to "Sell"Merus (MRUS) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - December 30 at 2:08 PM
Merus NV (MRUS) Expected to Announce Quarterly Sales of $2.72 MillionMerus NV (MRUS) Expected to Announce Quarterly Sales of $2.72 Million
www.americanbankingnews.com - December 28 at 2:26 PM
Merus NV (NASDAQ:MRUS): Should The Future Outlook Worry You?Merus NV (NASDAQ:MRUS): Should The Future Outlook Worry You?
finance.yahoo.com - December 27 at 5:55 PM

SEC Filings

Merus (NASDAQ:MRUS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Merus (NASDAQ:MRUS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Merus (NASDAQ MRUS) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.